Dr. Jonathan A. Moore
Pulmonology (Pulmonary Disease Physician)
9250 N 3rd St Ste 2030
Phoenix, AZ 85020
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 154
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
AZ license 70643 -
Internal Medicine Physician
NY license 302603 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Honor Health John C. Lincoln Medical Center Phoenix, AZ
- Honorhealth Scottsdale Shea Medical Center Scottsdale, AZ
- Honorhealth Scottsdale Osborn Medical Center Scottsdale, AZ
- Honorhealth Scottsdale Thompson Peak Med Ctr Scottsdale, AZ
Medical groups
- Honorhealth Ambulatory (630 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 154
- Services billed
- 628
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 34 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Phoenix, AZ | 64 |
| Spironolactone Other prescribers in Phoenix, AZ | 48 |
| Jardiance (empagliflozin) Other prescribers in Phoenix, AZ | 40 |
| Tadalafil | 34 |
| Bumetanide Other prescribers in Phoenix, AZ | 34 |
| Adempas (riociguat) | 33 |
| Potassium Chloride Other prescribers in Phoenix, AZ | 30 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Phoenix, AZ | 26 |
| Pantoprazole Sodium Other prescribers in Phoenix, AZ | 21 |
| Opsumit (macitentan) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 51 payments worth $5,653 in total to this clinician.
| Actelion Pharmaceuticals US, Inc. | $4,682 |
|---|---|
| United Therapeutics Corporation | $342 |
| Bayer HealthCare Pharmaceuticals Inc. | $200 |
| Johnson & Johnson Health Care Systems Inc. | $181 |
| Merck Sharp & Dohme LLC | $111 |
| Ani Pharmaceuticals, Inc. | $57.14 |
| Baxter Healthcare | $48.02 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.23 |
| Consulting Fee | $4,205 |
|---|---|
| Food and Beverage | $1,298 |
| Education | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Oct 24, 2025 | Consulting Fee OPSYNVI · Pulmonary Hypertension | $3,510 |
| Actelion Pharmaceuticals US, Inc. Dec 12, 2025 | Consulting Fee UPTRAVI · Cardiology | $495 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| Actelion Pharmaceuticals US, Inc. Sep 25, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $99.00 |
| Merck Sharp & Dohme LLC May 28, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Merck Sharp & Dohme LLC May 27, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $68,950 in research payments for these studies, mostly to the institutions running them.
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics Corporation · Active, not recruiting · NCT05203510
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.